Influence of CYP3A422 and CYP3A53 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.

Abdel-Hameed Ibrahim Mohamed EbidDina Ahmed Ismail Neama M LotfyMohamed Adel MahmoudMagdy ELSharkawy

Published in: Journal of clinical pharmacy and therapeutics (2022)

Pharmacogenetics testing for CYP3A4*22 and CYP3A5*3 before renal transplantation may help in the adjustment of tacrolimus starting dose and identify patients at risk of tacrolimus overexposure or underexposure.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes
patient reported